Trial Profile
Combination Daclizumab/Denileukin Diftitox (Ontak) Therapy for the Induction of Immune Tolerance in Non-infectious Intermediate and Posterior Uveitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary) ; Denileukin diftitox (Primary)
- Indications Intermediate uveitis; Posterior uveitis
- Focus Therapeutic Use
- 31 Jan 2017 New trial record